Jcr Pharmaceuticals Co., Ltd.

Aya Yoshioka

Kenichi Takahashi

Hideto Morimoto

Masafumi Kinoshita

Yuri Koshimura

Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.

Human serum albumin mutant

Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.

Growing community of inventors

Hyogo, Japan

Aya Yoshioka